FY2025 EPS Estimate for Perspective Therapeutics Lifted by Analyst

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Stock analysts at Brookline Capital Management upped their FY2025 earnings per share (EPS) estimates for shares of Perspective Therapeutics in a research report issued to clients and investors on Wednesday, November 12th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($1.32) for the year, up from their prior estimate of ($1.33). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). The business had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.21 million. Perspective Therapeutics had a negative net margin of 7,688.50% and a negative return on equity of 33.37%.

A number of other equities research analysts have also issued reports on CATX. BTIG Research initiated coverage on shares of Perspective Therapeutics in a research note on Friday, October 10th. They set a “buy” rating and a $14.00 target price for the company. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. B. Riley lowered their target price on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd. Four investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Perspective Therapeutics has an average rating of “Buy” and an average price target of $11.78.

Perspective Therapeutics Price Performance

CATX stock opened at $2.28 on Monday. The firm has a 50 day simple moving average of $3.20 and a 200 day simple moving average of $3.32. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $7.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 15.09 and a current ratio of 15.09.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CATX. Taylor & Morgan Wealth Management LLC increased its holdings in shares of Perspective Therapeutics by 4.4% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock valued at $323,000 after acquiring an additional 4,000 shares during the last quarter. Nicholson Wealth Management Group LLC boosted its holdings in shares of Perspective Therapeutics by 0.3% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock worth $5,553,000 after buying an additional 5,000 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the period. MetLife Investment Management LLC grew its stake in Perspective Therapeutics by 40.9% in the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after buying an additional 9,082 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its holdings in Perspective Therapeutics by 81.8% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock worth $100,000 after acquiring an additional 13,168 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.